Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases
Affiliations
- PMID: 19943211
Item in Clipboard
Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases
IDrugs.
2009 Dec.
Abstract
The 39th Annual Meeting of the Society for Neuroscience (SFN), held in Chicago, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on novel neuroprotective and antiparkinsonian agents, and compounds in development for the treatment of dementia, schizophrenia, depression, obesity and spinal muscular atrophy. Investigational drugs discussed include velusetrag and TD-8954 (both from Theravance Inc), SEP-228791 and SEP-226330 (both from Sepracor Inc), ADL-5510 (Adolor Corp), PF-217830 (Pfizer Inc), KB-099520 (Karo Bio AB), tesofensine (NeuroSearch A/S) and TRP6-01 (Theraptosis).
Similar articles
-
Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain.IDrugs. 2009 Dec;12(12):731-3. IDrugs. 2009. PMID: 19943210
-
Clinical trials in CNS--SMi's eighth annual conference.IDrugs. 2010 Feb;13(2):66-9. IDrugs. 2010. PMID: 20127552
-
European Neuroscience--Seventh Biennial FENS Forum.IDrugs. 2010 Sep;13(9):607-9. IDrugs. 2010. PMID: 20799140
-
Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.Mol Cell Neurosci. 1998 Nov;12(4-5):179-93. doi: 10.1006/mcne.1998.0714. Mol Cell Neurosci. 1998. PMID: 9828084 Review.
-
Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.Pharm Pat Anal. 2012 May;1(2):177-92. doi: 10.4155/ppa.12.19. Pharm Pat Anal. 2012. PMID: 24236782 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous